Welcome to our dedicated page for Csl news (Ticker: CSLLY), a resource for investors and traders seeking the latest updates and insights on Csl stock.
CSL Limited (CSLLY) regularly issues news about its biotechnology, biopharma and vaccine activities through its businesses CSL Behring, CSL Seqirus and CSL Vifor. Company announcements highlight regulatory milestones, clinical trial results and product updates across haemophilia, hereditary angioedema, influenza prevention, nephrology and other serious disease areas.
Recent news includes detailed Phase 3 data on HEMGENIX, a gene therapy for adults with hemophilia B, with five-year follow-up results from the HOPE-B trial describing factor IX activity, bleed rates and safety outcomes. CSL has also reported multiple regulatory approvals for ANDEMBRY, a factor XIIa-inhibiting monoclonal antibody used as a once-monthly prophylactic treatment to prevent hereditary angioedema attacks, including decisions by authorities in regions such as the European Union, Australia, the United Kingdom, Japan and the United States.
Through CSL Seqirus, the company publishes real-world evidence studies on cell-based quadrivalent influenza vaccines and their relative effectiveness compared with standard egg-based vaccines, as well as updates on influenza seasons and vaccine technologies. CSL and Arcturus Therapeutics have also announced European Commission marketing authorization for KOSTAIVE, described as the first self-amplifying mRNA COVID-19 vaccine approved in the European Union.
CSL Vifor news focuses on nephrology and iron deficiency, including regulatory and guideline developments for FILSPARI (sparsentan) in IgA nephropathy, such as European Commission decisions and guidance from organizations like England’s National Institute for Health and Care Excellence. Investors and observers following CSLLY news can use this page to review company communications on clinical evidence, regulatory approvals and product availability across CSL’s therapeutic portfolio.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
FAQ
What is the current stock price of Csl (CSLLY)?
What is the market cap of Csl (CSLLY)?
